Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus OPTIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus OPTIMINE.
LEVOCETIRIZINE HYDROCHLORIDE vs OPTIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
OPTIMINE (azathioprine) is a purine analog that inhibits DNA and RNA synthesis by interfering with purine metabolism. It is metabolized to 6-mercaptopurine, which inhibits de novo purine synthesis and suppresses T-lymphocyte proliferation.
Oral, 5 mg once daily in the evening.
1 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
Terminal elimination half-life of 12-15 hours in healthy adults, prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Renal: 65-75% as unchanged drug; biliary/fecal: 20-30% as metabolites; minor hepatic metabolism via CYP3A4.
Category A/B
Category C
Antihistamine
Antihistamine